What Are The Key Trends And Developments In Injectable Drug Formulation And Delivery?

Source: Pfizer CentreOne Sterile Injectables
Syringes GettyImages-171324030

The parenteral injectables market is rapidly growing and expected to reach $150.65 billion by 2028. This growth is driven by the expanding biopharmaceuticals industry – in which biologics are increasingly being used to treat chronic conditions like arthritis and diabetes – as well as the billions of messenger ribonucleic acid (mRNA) inoculations that continue to be delivered globally. This growth is putting pressure on biologics CDMOs to expand their capacity and explore more efficient ways to speed up production while also providing a shorter path to market.

The greater focus on patient-centric treatment is evolving the services that manufacturing partners need to offer, shifting the emphasis on contemporary drug design from simply preserving basic quality attributes – such as safety, efficacy, and potency in a simple container – to more complex formulations that preserve the value of the drug while providing additional benefits, including precise easy-to-administer delivery systems for better dose compliance. This focus on innovations in injectable devices requires CDMOs to advance their drug delivery capabilities to meet patient needs and expectations. Explore the barriers facing manufacturers and how to best evaluate a drug substance's characteristics and determine the most appropriate delivery device.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.

Subscribe to Drug Delivery Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Delivery Leader